pulmonary disease – Page 42 – Communicable Diseases Research

Multi-organ Dysfunction in Patients with COVID-19: A Systematic Review and Meta-analysis

Review

Published on 2020-07-132022-10-28
Journal: Aging and Disease [Category] COVID-19,

Identifying Patients at Greatest Risk of Mortality due to COVID-19: A New England Perspective

Endemic Infections

Published on 2020-07-082022-10-28
Journal: Western Journal of Emergency Medicine [Category] COVID-19, SARS,

[키워드] 95% CI 95% confidence interval acute respiratory syndrome age Analysis being can be used Care chronic obstructive Comorbidities confirmed case Connecticut COPD coronavirus COVID-19 patient deaths Deceased diabete died discharged distribution England examined Factor frontline healthcare worker Generalized linear model HCW Health hospital Hospitalized hospitalized COVID-19 patients identify identifying in-hospital mortality likelihood log Massachusett Mortality New Older outcome pandemic Patient physical PROTECT protective effect public health pulmonary disease reducing Result resulting retrospective cohort study risk risk factor SARS-CoV-2 severe disease specificity Spread Trinity was increased
[DOI] 10.5811/westjem.2020.6.47957 PMC 바로가기 [Article Type] Endemic Infections

Acute Effusive Pericarditis: A Late Complication of COVID-19

Cardiology

Published on 2020-07-082022-10-31
Journal: Cureus [Category] COVID-19,

Failure of early extubation among cases of coronavirus disease-19 respiratory failure Case report and clinical experience

3900

Published on 2020-07-022022-10-30
Journal: Medicine [Category] COVID-19, SARS,

[키워드] adopted Antiviral Antiviral treatment Care carried chronic obstructive clinical experience conducted coronavirus disease 19 Coronavirus disease-19 criteria Elderly patient Endotracheal intubation expected extracorporeal membrane oxygenation extubation extubation criteria failure Hospitalization iatrogenic Infection Injury intubation likelihood mechanical ventilation mechanically ventilated patient noninvasive respiratory onset of fever Oxygenation Patient progressed progression Prone position pulmonary disease receive receiving reduce rehabilitation reintubation reported Respiratory failure sputum Strategy Support Supportive treatment symptomatic the disease therapy tracheal transferred Treatment upper respiratory tract Viral pneumonia was performed
[DOI] 10.1097/MD.0000000000020843 PMC 바로가기 [Article Type] 3900

Risk factors for 2019 novel coronavirus disease (COVID-19) patients progressing to critical illness: a systematic review and meta-analysis

Review

Published on 2020-06-302022-10-28
Journal: Aging (Albany NY) [Category] COVID-19, SARS,

[키워드] 2019 novel coronavirus agency albumin article body mass index C-reactive protein cardiovascular disease Chinese chronic obstructive Combination conducted COVID-19 COVID-19 cases COVID-19 patient COVID-19 patients Critical develop diabetes disease Dyspnea effective therapy elevated eligible English Evidence Factor Fever had more Health hypertension Laboratory test lactate dehydrogenase liver enzymes lymphocyte male Medical resources Meta-analysis Mild mild cases non-severe patients pandemic Patient patients prevalent procalcitonin pulmonary disease Research resource rising risk factor Risk factors second severe COVID-19 infections Severe patient Stata strained Symptom systematic review underlying disease Vaccine virus was used White blood cell
[DOI] 10.18632/aging.103383 PMC 바로가기 [Article Type] Review

Clinical and CT findings of COVID-19: differences among three age groups

Research Article

Published on 2020-06-222022-10-28
Journal: BMC Infectious Diseases [Category] COVID-19, SARS,

Distribution of Patients at Risk for Complications Related to COVID-19 in the United States: Model Development Study

Original Paper

Published on 2020-06-182022-10-31
Journal: JMIR Public Health and Surveillance [Category] COVID-19,

[키워드] Accuracy Admission Adult patient age anticipated approach ArcMap association average calculated Care center chronic conditions chronic obstructive Comorbidities Complication complications contribute COVID-19 COVID-19 case COVID-19 infection Critical data set develop development diabete disease distribution of patient eligible Engineering estimate Health health condition high risk highest Hospitalization hypertension ICU identify IMPROVE intensive care Johns Hopkins University life-threatening medication Model modeling MOST non-ICU number of comorbidity objective older adult Older adults parameter Patient Pharmacy populations Prevent Prognosis pulmonary disease reported resource Result risk Science serious complication severe complication severe complications severe COVID-19 Spread spread of COVID-19 System the patient the United State The United States treated Walgreen was used
[DOI] 10.2196/19606 PMC 바로가기 [Article Type] Original Paper

COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study

Research article

Published on 2020-06-122022-10-05
Journal: The Lancet. Oncology [Category] SARS, 유전자 메커니즘,

[키워드] 95% CI acute respiratory syndrome addition Admission admitted to ICU age Analysis Cancer Cardiopulmonary Chemotherapy chronic obstructive clinical Clinical characteristics Clinical outcome Cohort cohort study collaboration collected Comorbidities Comorbidity composed consecutive patient Cooperative coronavirus country Course COVID-19 COVID-19 diagnosis COVID-19 in patient criteria cross-sectional death demographics died eight eligible epithelial feature finding Follow-up funding General population global pandemic group high mortality high mortality rate histology hospitalised hypertension ICU admission increased risk Infection intensive care International Laboratory lung cancer Lung imaging majority median age medical record Mortality multicentre multivariable analysis multivariable logistic regression Neoplasms neuroendocrine Odds ratio Older Older age outcome pandemic Patient patient data patients Patients with cancer patients with COVID-19 performance status Pneumonia pulmonary disease receiving reduced RT-PCR SARS-CoV-2 Sex smoker smoking smoking status suggested susceptible Symptom Symptoms therapeutic options therapy Thoracic Thoracic malignancies Thoracic malignancy thought thymic Treatment Tumours univariable were measured WHO with COVID-19
[DOI] 10.1016/S1470-2045(20)30314-4 [Article Type] Research article

Current status of mesenchymal stem cell therapy for immune/inflammatory lung disorders: Gleaning insights for possible use in COVID ‐19

Concise Review

Published on 2020-06-112022-10-28
Journal: Stem cells translational medicine [Category] COVID-19, MERS,

[키워드] accompanied accumulated acute respiratory distress Allogeneic ARDS Asthma Bacterial bacterial pneumonia chronic obstructive clinical trial Clinical use COPD COVID COVID‐19 COVID‐19 curative current Cytokine storm disease Diseases disorder disorders Effect effective Evidence Gleaning Idiopathic pulmonary fibrosis immunomodulatory property Influenza lack lung lung disorders mesenchymal stem cell Mesenchymal stem cells mortality rate MSC MSC therapy MSCs novel coronavirus disease outcomes pandemic Perspective preclinical data pulmonary conditions pulmonary disease pulmonary injury regenerative reported stem cell Stem cell therapy syndrome therapeutic therapeutic use therapy
[DOI] 10.1002/sctm.20-0186 PMC 바로가기 [Article Type] Concise Review

Efficacy and safety of Anluohuaxian in the treatment of patients with severe Coronavirus disease 2019- a multicenter, open label, randomized controlled study: a structured summary of a study protocol for a randomised controlled trial

Letter

Published on 2020-06-082022-10-29
Journal: Trials [Category] Coronavirus, SARS,

[키워드] 6-minute walking distance actual Alpha analyst Anluohuaxian antiviral drugs brand bronchial asthma Care change changes Chinese Chinese herbal medicines chronic obstructive Colchicine Combined completion Compliance composed computer tomography Confirmed connective tissue control group Coronavirus disease 2019 COVID-19 criteria Cyclophosphamide cytokine diagnosed dissemination distribution drug Efficacy and safety element Endocrine enrolled Estimated evaluate expected experimental group explained facilitate fibrosis glucocorticoid groups hepatic fibrosis High-resolution history Hormones HRCT Huoshenshan Hospital Imatinib include indicate interferon-γ interstitial Interstitial lung disease investigators involved IWRS Kidney disease lactating liver lobular lung maximum Mental Disorders minimum multicenter Nasopharyngeal swab Necrosis negative neurologic Nintedanib nodule not blinded nucleic acid test number objective open label outcome outcome assessors participant Participants Pathogenesis pathway Patient pharmaceutical pill professional proportion protocol provided pulmonary pulmonary disease pulmonary fibrosis random randomised randomised controlled trial randomization randomization system Randomized Randomized controlled trial randomly divided RCT recruitment Research research drug respiratory specimen Sample size Science second selected severe COVID-19 sputum statistical status Study protocol subject technology therapeutic drug Tongji Hospital treated Treatment treatment group Trial Union Hospital university variety website West Wuhan Year
[DOI] 10.1186/s13063-020-04399-8 PMC 바로가기 [Article Type] Letter